Complete Filing Data
Drugs Made In America Acquisition Corp. — complete XBRL filing history below.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Drugs Made In America Acquisition Corp. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|
| Net Income Loss | $2.2M | $2.3M | $1.3M | -$144.9K | -$54.9K |
| General And Administrative Expense | $263.7K | $131.9K | $330.9K | $144.9K | $54.9K |
| Operating Income Loss | -$263.7K | -$131.9K | -$330.9K | -$144.9K | -$54.9K |
| Nonoperating Income Expense | $2.4M | $2.4M |
Balance Sheet
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Stockholders Equity | -$7.3M | -$7.2M | -$7.2M | -$244.8K | -$164.9K | -$19.9K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $717.00 | $822.00 | $923.00 | $1.4K | $2.1K | $18.1K |
| Retained Earnings Accumulated Deficit | -$6.7M | -$6.5M | -$6.3M | -$279.8K | ||
| Prepaid Expense And Other Assets Current | $27.5K | $48.9K | $70.1K | $3.6K | ||
| Liabilities And Stockholders Equity | $237.6M | $235.2M | $232.8M | $550.8K | ||
| Liabilities | $7.4M | $7.2M | $7.2M | $795.7K | ||
| Common Stock Value | $1.1K | $1.1K | $1.1K | $986.00 | ||
| Assets Current | $28.2K | $49.7K | $71.0K | $5.0K | ||
| Assets | $237.6M | $235.2M | $232.8M | $550.8K | ||
| Accrued Offering Costs | $154.0K | $154.0K | $154.0K | $56.1K | ||
| Accrued Liabilities Current | $302.6K | $147.5K | $132.5K | $77.3K | ||
| Repayments Of Related Party Debt | $900.0K | $1.2M | $189.9K | |||
| Offering Costs Included In Accrued Offering Costs | $94.5K | $31.6K | $896.00 | |||
| Liabilities Current | $456.6K | $301.4K | $347.4K | $795.7K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$428.00 | $2.1K | $18.1K | |||
| Temporary Equity Accretion To Redemption Value | $2.4M | $14.9M | ||||
| Deferred Costs | $545.8K | |||||
| Temporary Equity Carrying Amount Attributable To Parent | $237.6M | $235.2M | $232.7M | |||
| Stockholders Equity Note Subscriptions Receivable | $608.8K | $695.8K | $852.4K | |||
| Share Subscription Receivable | $1.1M | |||||
| Expenses Paid By Sponsor Under Share Subscription Receivable | -$247.6K | |||||
| Deferred Underwriting Fee Payable | $6.9M | |||||
| Costs Included In Equity | $848.20 | |||||
| Assets Held In Trust Noncurrent | $237.6M | $235.2M | $232.7M | |||
| Deferred Underwriting Fees | $6.9M | $6.9M | ||||
| Deferred Compensation Liability Classified Noncurrent | $6.9M |
Cash Flow Statement
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$251.2K | -$172.2K | -$114.9K |
| Net Cash Provided By Used In Financing Activities | $231.4M | $174.3K | $133.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $70.1K | $60.0K | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $55.2K | $7.4K | |
| Proceeds From Sale Of Units Net Of Underwriting Discounts Paid | $228.9M | ||
| Proceeds From Related Party Debt | $1.7M | $375.0K | |
| Proceeds From Issuance Of Private Placement | $3.2M | ||
| Payments To Acquire Trust Preferred Investments | $231.2M | ||
| Net Cash Provided By Used In Investing Activities | -$231.2M | ||
| Proceeds From Issuance Of Common Stock | $35.0K | $35.0K |
Per-Share & Share Counts
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Preferred Stock Shares Authorized | 1.0M | 1.0M | 1.0M | 1.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 10.5M | 10.5M | 10.5M | 9.9M |
| Common Stock Shares Issued | 10.5M | 10.5M | 10.5M | 9.9M |
| Common Stock Shares Authorized | 220.0M | 220.0M | 220.0M | 220.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Temporary Equity Redemption Price Per Share | $10.33 | $10.22 | $10.12 | $0.00 |
| Temporary Equity Shares Outstanding | 23.0M | 23.0M | 23.0M | 0.00 |
| Sale Of Stock Number Of Shares Issued In Transaction | 430.0K |
Other Metrics
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Notes Issued1 | $204.0K | $29.5K | $25.0K | |||
| Payment Of Offering Costs | -$3.2K | $363.0K | $87.1K | |||
| Investment Income Interest | $2.4M | $2.4M | $1.6M | |||
| Stock Issued During Period Value New Issues | $3.2M | $35.0K | ||||
| Additional Paid In Capital | $34.0K | |||||
| Stock Redeemed Or Called During Period Value | $147.8K | |||||
| Stock Issued During Period Value Fair Value Of Representative Shares | 23.00 | |||||
| Operating Costs Paid Through Promissory Note | $94.6K | |||||
| Expenses Paid By The Sponsor | $87.0K | $156.6K | $247.6K | |||
| Adjustments To Additional Paid In Capital Mark To Market | $3.4M | |||||
| Adjustments To Additional Paid In Capital Expenses Paid By The Sponsor | $156.6K | $247.6K | ||||
| Adjustment Of Additional Paid In Capital Accretion And Remeasurement For Redeemable Ordinary Shares To Redemption Amount | 2.4M | 2.4M | 14.9M | |||
| Stock Issued During Period Value Other | $3.2M | |||||
| Operating Costs And Expenses | $20.3K |
Data sourced from SEC EDGAR public filings as of August 9, 2026.